Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma

Area of Science:

• Oncology
• Gastroenterology

Background:

• Small bowel cancers are rare, with poor prognoses, and lack optimized treatment regimens.
• Current treatments for advanced small bowel adenocarcinoma are often adapted from colorectal cancer protocols.

Purpose of the Study:

• To review evidence for targeted treatments beyond bevacizumab in metastatic small bowel adenocarcinoma.
• To explore potential benefits of agents targeting EGFR, VEGFR-2, HER2, NTRK, and immune checkpoint inhibitors.

Main Methods:

• Literature review of recent studies on targeted therapies for metastatic small bowel adenocarcinoma.
• Analysis of evidence supporting various targeted agents and immune checkpoint inhibitors.

Main Results:

• Bevacizumab is now included in treatment guidelines for metastatic small bowel adenocarcinoma.
• Immune checkpoint inhibitors show the most promise among the investigated targeted treatments.
• Data on the efficacy of these targeted therapies remains limited.

Conclusions:

• Targeted therapies, particularly immune checkpoint inhibitors, represent a promising avenue for managing metastatic small bowel adenocarcinoma.
• Ongoing clinical trials are crucial for refining treatment strategies and improving outcomes for this rare malignancy.